Dermata Therapeutics Stock Number Of Shares Shorted
| DRMA Stock | USD 1.14 0.01 0.87% |
Dermata Therapeutics fundamentals help investors to digest information that contributes to Dermata Therapeutics' financial success or failures. It also enables traders to predict the movement of Dermata Stock. The fundamental analysis module provides a way to measure Dermata Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dermata Therapeutics stock.
Dermata | Number Of Shares Shorted |
Dermata Therapeutics Company Number Of Shares Shorted Analysis
Dermata Therapeutics' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Dermata Therapeutics Number Of Shares Shorted | 93.74 K |
Most of Dermata Therapeutics' fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dermata Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Dermata Number Of Shares Shorted Driver Correlations
Understanding the fundamental principles of building solid financial models for Dermata Therapeutics is extremely important. It helps to project a fair market value of Dermata Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since Dermata Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Dermata Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Dermata Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Dermata Therapeutics has 93.74 K of outstending shares currently sold short by investors. This is 97.07% lower than that of the Biotechnology sector and 98.16% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 98.01% higher than that of the company.
Dermata Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dermata Therapeutics' direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dermata Therapeutics could also be used in its relative valuation, which is a method of valuing Dermata Therapeutics by comparing valuation metrics of similar companies.Dermata Therapeutics is currently under evaluation in number of shares shorted category among its peers.
Dermata Fundamentals
| Return On Equity | -1.73 | ||||
| Return On Asset | -0.91 | ||||
| Current Valuation | (3.82 M) | ||||
| Shares Outstanding | 2.04 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 0.66 % | ||||
| Number Of Shares Shorted | 93.74 K | ||||
| Price To Book | 0.49 X | ||||
| EBITDA | 247.22 K | ||||
| Net Income | (7.79 M) | ||||
| Cash And Equivalents | 10.63 M | ||||
| Cash Per Share | 1.05 X | ||||
| Total Debt | 1.62 M | ||||
| Current Ratio | 8.07 X | ||||
| Book Value Per Share | 24.25 X | ||||
| Cash Flow From Operations | (6.41 M) | ||||
| Short Ratio | 0.52 X | ||||
| Earnings Per Share | (13.36) X | ||||
| Target Price | 6.0 | ||||
| Beta | 0.79 | ||||
| Market Capitalization | 2.32 M | ||||
| Total Asset | 7.98 M | ||||
| Retained Earnings | (53.39 M) | ||||
| Working Capital | 6.36 M | ||||
| Net Asset | 7.98 M |
About Dermata Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dermata Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dermata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dermata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Dermata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dermata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dermata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dermata Therapeutics Stock:Check out Dermata Therapeutics Piotroski F Score and Dermata Therapeutics Altman Z Score analysis. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.36) | Return On Assets (0.91) | Return On Equity (1.73) |
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dermata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.